Publication: Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: Experience at a single, large care center
This research article, published in the Journal of Comparative Effectiveness Research, provides results from a retrospective real-world analysis of corticosteroid use in patients with Duchenne muscular dystrophy (DMD)
Find out about the background and demographics of the 435 boys included in this retrospective, real-world analysis
Read more about the comparison between clinical outcomes of corticosteroid treatments for DMD, as assessed by median age at loss of ambulation, incidence of scoliosis, lean body mass, stature, and weight
Review a cross-sectional analysis of the outcomes to further understand associations between steroid type and patient status
Marden JR, Freimark J, Yao Z, et al. J Comp Eff Res. 2020;9(3):177–189
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200118 | May 2022
Sign in or register to access exclusive content on this site